BioxyneASX:BXNDA -2.06%50 ROE % is 90.14% as of Dec. 2025. GuruFocus rates ASX:BXNDA with a GF Score™ of 50/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,916 Consumer Packaged Goods companies, Bioxyne ranks better than 97.49% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Bioxyne's annualized net income for the quarter that ended in Dec. 2025 was A$14.68 Mil. Bioxyne's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was A$16.29 Mil. Therefore, Bioxyne's annualized ROE % for the quarter that ended in Dec. 2025 was 90.14%.
The historical rank and industry rank for Bioxyne's ROE % or its related term are showing as below:
ASX:BXNDA'
s ROE % Range Over the Past 10 Years
Min: -142.19 Med: -22.04 Max: 67.62
Current: 67.62
During the past 13 years, Bioxyne's highest ROE % was 67.62%. The lowest was -142.19%. And the median was -22.04%.
ASX:BXNDA's ROE % is ranked better than 97.49% of 1916
companies
in the Consumer Packaged Goods industry
Industry Median: 6.735
vs ASX:BXNDA: 67.62
Bioxyne (ASX:BXNDA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Bioxyne ROE % Related Terms
Bioxyne ROE % Historical Data
* Premium members only.
The historical data trend for Bioxyne's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Bioxyne's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioxyne ROE % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioxyne's ROE % distribution charts can be found below:
* The bar in red indicates where Bioxyne's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Bioxyne (ASX:BXNDA) has a ROE % of 90.14% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bioxyne and its competitors. According to the industry distribution chart, Bioxyne ranks #48 out of 1916 companies in the Consumer Packaged Goods industry, placing it in the top 2.5%.
Is Bioxyne's ROE % too high?
Bioxyne's current ROE % is 90.14%. The Consumer Packaged Goods industry median ROE % is 6.74. Bioxyne's value of 90.14% is 1238.4% above this industry median. Based on the distribution chart, Bioxyne ranks #48 out of 1916 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Bioxyne has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioxyne's ROE % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Bioxyne ranks #48 out of 1916 companies for ROE %. This places Bioxyne in the top 3% of its industry — outperforming the majority of peers. The industry median ROE % is 6.74. Bioxyne's value of 90.14% is 1238.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Consumer Packaged Goods company?
The median ROE % among Consumer Packaged Goods companies is 6.74, based on 1,916 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioxyne's current ROE % of 90.14% is 1238.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Bioxyne and its competitors. For the Consumer Packaged Goods industry, the median ROE % is 6.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioxyne's current ROE % is 90.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxyne stock overvalued right now?
Based on GuruFocus' analysis, Bioxyne (ASX:BXNDA) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.95 — trading 37.7% above its estimated fair value. The current ROE % is 90.14% and 1238.4% above the Consumer Packaged Goods industry median of 6.74. Bioxyne's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Bioxyne (ASX:BXNDA), the current ROE % is 90.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioxyne (ASX:BXNDA) Overvalued in 2026?
Based on GuruFocus' analysis, Bioxyne stock appears to be overvalued.
The current stock price of A$0.95 is trading 37.7% above its estimated GF Value™ of A$0.69.
GuruFocus considers Bioxyne to be Significantly Overvalued.
Key valuation signals for ASX:BXNDA:
ROE %: 90.14%
GF Value™: A$0.69 vs. price of A$0.95 (37.7% above fair value)
Industry Position: 1238.4% above the Consumer Packaged Goods median (#48 of 1916)
No single metric tells the full story. See the ASX:BXNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
50GF Score
Get the complete analysis for ASX:BXNDA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BXNDA has been successfully added to your 
